Supply Chain

In the second part of her interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, discusses the best practices that compliance teams should consider as the end of the stabilization period approaches this November.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Ilisa B.G. Bernstein, President of Bernstein Rx Solutions, LLC, highlights the hard-hitting points that she anticipated will be covered during her session at the 2024 HDA Traceability Seminar.

How can industry stakeholders ensure the quality and supply chain security of existing product?

The 8,000 square-foot facility—located within the wholesaler’s Le Vergne distribution center— is expected to help tackle cell and gene therapy logistical challenges.

The 3PL plans to convert all its trucks to electric by 2027.

Panel offers suggestions on how compliance teams should be considering handling SOPs, stabilization, and much more.

Session uncovers distributors’ experiences with the Waiver, Exception, or Exemption request process, and how these affect the overall supply chain.

Ryan Sevek, the supplier’s CFO, will become president.

Chris Williams expands on the services that a third-party logistics (3PL) partner should offer, while sharing ways to alleviate standard supply chain issues.

A prediction of how this shift toward patient-centric care may look.

The unveiling of the microbial fermentation manufacturing plant is headlined by a $131 million financial commitment.

The 86,000 square-foot Køge facility will be fully functional by 2027.

In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, comments on other ways to limit ‘bad actors’ attempts to sneak counterfeit drugs into the supply chain, aside from the DSCSA.

Partnership adds supply chain efficiencies, while prioritizing patient safety.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, predicts the likelihood of stabilization period postponement.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, describes the outcome of the joint public meeting held by the Partnership for DSCSA Governance and the FDA.

The partnership creates an integrated solution that also tackles compliance challenges within the sector.

Even as pharma technology evolves, and payers argue over reimbursement practices throughout healthcare, drug wholesaling is a thriving business.

In this part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, discusses the state of affairs surrounding the Drug Supply Chain Security Act, along with opportunities for improvement.

In an interview with Pharma Commerce Editor Nicholas Saraceno, Michael Rowe, Two Labs’ Senior Director of DSCSA/Serialization Compliance Services, offers a brief overview of the Drug Supply Chain Security Act.

Per the deal, DKSH inherits the specialty pharma company’s Asia-Pacific medication portfolio.

In the final portion of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, discusses the value in needle-to-needle and precision logistics, including its impact over the course of the next five years.

In this part of his Pharma Commerce video interview, Dan Gagnon, UPS Healthcare’s VP of Global Strategy & Acquisition Integration, dives into the challenges of safeguarding these products, while also sharing his keys to sustaining stability in the ‘recession resistant’ healthcare industry.

The climb is headlined by a 14.1% increase in total demand, according to the IATA.

Peter Ax provides insight as to industry’s lack of supply, along with how to mitigate these issues.